Ming Zhou
机构：Tang Hospital · ORCID：0009-0006-2055-7756
发表论文 22 篇 · 总被引 1039 次 · h-index 12
代表论文
- Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer (2024 · JAMA · 被引 358)
- Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant (2024 · JAMA · 被引 186)
- Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China (2025 · The Lancet · 被引 150)
- AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial (2023 · EClinicalMedicine · 被引 104)
- First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial (2024 · The Lancet Respiratory Medicine · 被引 58)
- Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)